GlassScriptPhysician profile
Reed Evans Cope
NPI 1801214267
$11,923.15
in general payments reported to CMS, 2019-2025
64 companies · $2,717 in 2025
The $2,717 reported for 2025 was more than what 92% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $235 · 2020: $724 · 2021: $1,115 · 2022: $2,117 · 2023: $2,282 · 2024: $2,733 · 2025: $2,717.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,515 · Education: $217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,515.22 |
| Education | $216.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $1,883.39 | 2019-2025 | Optune, Optune Gio |
| Merck Sharp & Dohme LLC | $1,096.06 | 2020-2025 | Keytruda, Welireg, Keytruda Qlex |
| Janssen Biotech, INC. | $933.53 | 2020-2025 | Erleada, Darzalex, Talvey |
| Novartis Pharmaceuticals Corporation | $878.60 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $649.04 | 2021-2025 | Enhertu, Lynparza |
| Seagen INC. | $532.11 | 2020-2023 | Tukysa, Adcetris, Padcev |
| Abbvie INC. | $443.42 | 2020-2025 | Venclexta |
| Pfizer INC. | $417.96 | 2020-2025 | |
| Gt Medical Technologies, INC | $363.86 | 2022-2025 | Gammatile |
| Eisai INC. | $343.30 | 2020-2025 | |
| Incyte Corporation | $336.14 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Lilly USA, LLC | $319.08 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Genzyme Corporation | $295.95 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $275.77 | 2022-2025 | Libtayo |
| Genentech USA, INC. | $258.32 | 2023-2025 | Phesgo, Tecentriq, Perjeta |
Show all 63 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reed Cope listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.